In the BioHarmony Drug Report Database

"Preview" Icon

Ozanimod

Zeposia (ozanimod) is a small molecule pharmaceutical. Ozanimod was first approved as Zeposia on 2020-03-25. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 2, sphingosine 1-phosphate receptor 4, and sphingosine 1-phosphate receptor 3. Zeposia’s patents are valid until 2030-11-15 (FDA).

 

Trade Name

 

Zeposia
 

Common Name

 

ozanimod
 

ChEMBL ID

 

CHEMBL3707247
 

Indication

 

relapsing-remitting multiple sclerosis
 

Drug Class

 

Immunomodulators

Image (chem structure or protein)

Ozanimod structure rendering